Marker Therapeutics, Inc. (NASDAQ:MRKR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) have been assigned a consensus rating of “Moderate Buy” from the five analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $11.25.

A number of research analysts recently issued reports on the company. UBS Group reiterated a “buy” rating on shares of Marker Therapeutics in a report on Monday, December 8th. HC Wainwright began coverage on Marker Therapeutics in a research report on Monday, December 8th. They set a “buy” rating and a $10.00 price target for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Marker Therapeutics in a research note on Monday, December 22nd. Zacks Research downgraded shares of Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Finally, Wall Street Zen upgraded Marker Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new position in shares of Marker Therapeutics during the 2nd quarter worth approximately $33,000. Virtu Financial LLC acquired a new stake in shares of Marker Therapeutics in the 3rd quarter valued at approximately $25,000. Two Sigma Investments LP acquired a new stake in shares of Marker Therapeutics in the 3rd quarter valued at approximately $33,000. Boyer Financial Services Inc. bought a new position in shares of Marker Therapeutics in the fourth quarter valued at $57,000. Finally, XTX Topco Ltd grew its stake in shares of Marker Therapeutics by 166.6% in the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock valued at $86,000 after buying an additional 36,269 shares in the last quarter. 22.39% of the stock is currently owned by institutional investors.

Marker Therapeutics Trading Down 3.8%

Shares of NASDAQ MRKR opened at $1.26 on Wednesday. The company has a fifty day moving average price of $1.57 and a 200 day moving average price of $1.31. The firm has a market cap of $21.00 million, a PE ratio of -1.48 and a beta of 1.42. Marker Therapeutics has a 1-year low of $0.81 and a 1-year high of $4.07.

Marker Therapeutics (NASDAQ:MRKR) last released its quarterly earnings results on Wednesday, March 18th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.17. The firm had revenue of $1.10 million for the quarter, compared to the consensus estimate of $0.68 million. Marker Therapeutics had a negative return on equity of 80.86% and a negative net margin of 343.03%. Equities research analysts forecast that Marker Therapeutics will post -0.65 EPS for the current year.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.